Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ11 | Q14654 | 4/20 | 0.42 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.42 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.42 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.42 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8171726 | 0.85 | NCEH1 (0.44) | KCNJ11ABCC9ABCC8KCNJ8NCEH1 | |
| SCHEMBL27937799 | 0.83 | KCNH2 (0.42) | KCNJ11ABCC9ABCC8KCNJ8NCEH1 | |
| SCHEMBL11517897 | 0.82 | MEN1 (0.47) | KCNJ11ABCC9ABCC8KCNJ8NCEH1 | |
| SCHEMBL10967385 | 0.81 | ACP3 (0.45) | KCNJ11ABCC9ABCC8KCNJ8NCEH1 | |
| SCHEMBL23367961 | 0.79 | KDM4E (0.43) | KCNJ11ABCC9ABCC8KCNJ8ATM | |
| SCHEMBL27680069 | 0.79 | KDM1A (0.46) | G6PDATMMEN1KMT2ASLC2A1 | |
| SCHEMBL1402654 | 0.76 | CYP2A6 (0.46) | NCEH1ATMALDH1A1CYP2A6TSHR | |
| SCHEMBL887267 | 0.75 | KDM1A (0.51) | MEN1KMT2AALDH1A1 | |
| SCHEMBL2167788 | 0.75 | — | — | |
| SCHEMBL29886792 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308653-B2 | Diazepane derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308653-B2 | Diazepane derivatives and uses thereof | BRDT, BRD4, BAZ2A | KCNJ11 3612/4885ABCC9 2961/4885ABCC8 2518/4885 |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BAZ2A | KCNJ11 3612/4885ABCC9 2961/4885ABCC8 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.